WuXi AppTec Co., Ltd., an investment holding firm, specializes in providing a full spectrum of research, development, and manufacturing services. The company's expertise is leveraged globally to facilitate the discovery, advancement, and production of both small molecule pharmaceuticals and innovative cell and gene therapies. Its operational reach extends throughout the People's Republic of China, across the broader Asian continent, within the United States, and across Europe. The organization is structured into six distinct divisions: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and a collective "Others" segment. WuXi AppTec offers comprehensive contract research, development, and manufacturing (CRDMO) capabilities, supporting new drug candidates from their initial discovery phases all the way to commercial launch. This support covers a diverse array of synthetic molecular compounds, such as small molecules, oligonucleotides, peptides, and intricate conjugates. Additionally, the company delivers biology services and solutions that underpin standalone or integrated projects, ranging from target identification to candidate selection and subsequent clinical progression. The firm also provides streamlined testing services for drugs and medical devices, spanning from preclinical evaluation to full-scale clinical trials. It further distinguishes itself by offering an integrated, end-to-end solution specifically designed to expedite the market entry of cell and gene therapies. Complementary services include drug discovery assistance for pharmaceutical and biotechnology clients, as well as comprehensive clinical research services. Founded in the year 2000, WuXi AppTec Co., Ltd. maintains its headquarters in Shanghai, People's Republic of China.